News

Filter

Current filters:

aflibercept

Approved cancer drug potentially could help treat diabetes, Stanford researchers find

16-09-2013

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…

afliberceptBayerBiotechnologyDiabetesEyleaOncologyPharmaceuticalRegeneronResearchSanofiZaltrap

Bayer files for Japanese approval of Eylea for macular edema following CRVO

07-01-2013

German drug major Bayer(BAYN: DE) says its subsidiary Bayer Yakuhin has applied to the Japanese Ministry…

afliberceptAsia-PacificBayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronRegulationSanten Pharmaceuticals

Bayer to file for EU approval of aflibercept for central retinal vein occlusion

21-02-2012

German drug major Bayer (BAY: DE) says that it will file for European approval of its macular edema treatment…

afliberceptBayerEuropeEyleaOphthalmicsPharmaceuticalRegeneronRegulationResearch

Sanofi-Aventis and Regeneron’s Zaltrap improves OS in Ph III colon cancer study

28-04-2011

French drug major Sanofi-Aventis (Euronext: SAN) and USA-based partner Regeneron Pharmaceuticals (Nasdaq:…

afliberceptOncologyPharmaceuticalRegeneronResearchSanofi-AventisZaltrap

Sanofi-Aventis/Regeneron’s aflibercept fails in Ph III NSCLC study

14-03-2011

Results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for…

afliberceptOncologyPharmaceuticalRegeneronResearchSanofi-Aventis

Ph III studies show Bayer and Regeneron VEGF Trap-Eye in wet AMD meets primary endpoints versus Lucentis

22-11-2010

German drug major Bayer (BAY: DE) and US partner Regeneron Pharmaceuticals (Nasdaq: REGN) reveal that,…

afliberceptBayerLucentisNovartisOpthalmicsPharmaceuticalRegeneronResearchRocheVEGF Trap-Eye

COMPANY SPOTLIGHT

Menarini

Back to top